DIA and the Brookings Institution to Join Forces

Understanding and Anticipating Payer Requirements Is Essential for Successful Product Launches

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

DIA log

Communication among these three critical stakeholders often occurs far too late in the product development cycle.

HORSHAM, Pa. (PRWEB) October 09, 2013

DIA will partner with the Engelberg Center for Health Care Reform at the Brookings Institution to engage stakeholder groups to identify promising approaches for communication among patients, payers and product developers throughout the product life cycle to define value, advance innovation and improve quality in the health care system. This first-ever conference between DIA and Brookings, A Model of Patient, Payer, and Product Developer Collaboration to Support Innovating for Value, will be held Oct. 30-31 at Washington Marriott Wardman Park in Washington, D.C.

“This conference and our collaboration with Brookings provide an opportunity for two leaders in global health care to come together to facilitate novel communication among patients, payers and product developers,” said Barbara Kunz, DIA’s global chief executive. “Communication among these three critical stakeholders often occurs far too late in the product development cycle. This meeting will advance the discussions for collaborative development of better designs for burden-of-disease studies and health technology assessments that produce meaningful results.”

The two-day conference will focus on:

  •     Tools for communication among patients, payers and product developers
  •     Product developers’ perspectives on the role of patients and payers in driving value-based innovation
  •     Patients’ perspectives on desired health outcomes
  •     Payers’ perspectives on reimbursement requirements and innovative payment models
  •     Strategies and mechanisms to improve stakeholder communication

“Health care reform is creating more and more pressure to improve outcomes and deliver high-quality care. This is especially challenging in light of concerns about the efficiency and predictability of the development process,” said Mark B. McClellan, M.D., Ph.D., senior fellow of the Health Care Innovation and Value Initiative at Brookings Institution. “The conference will address not only what ‘value’ means to everyone involved, but also practical, effective ways to incorporate those perspectives throughout the process of developing and paying for innovative medical products.”

The meeting will pave the way for discussing new approaches for communication among patients, payers and product developers throughout the product life cycle to define value and improve innovation and quality in the health care system. Furthermore, participants will define a vision for more effective collaborative communication and engagement among stakeholders and identify steps toward achieving that goal.

The following program committee, comprised of thought leaders in an array of patient, payer and product arenas, will drive the two-day discussion:

Program Committee
Christine K. Cassel, M.D., President and CEO, National Quality Forum
Margaret Anderson, M.S., Executive Director, FasterCures
Anne C. Beal, M.D., MPH, Deputy Executive Director and Chief Operating Officer for Engagement, Patient-Centered Outcomes Research Institute
Hans-Georg Eichler, M.D., M.S., Senior Medical Officer, European Medicines Agency, U.K.
Richard E. Kuntz, M.D., M.S., Senior Vice President; Chief Scientific, Clinical and Regulatory Officer, Medtronic
Shari M. Ling, M.D., Deputy Chief Medical Officer, Centers for Medicare & Medicaid Services; Center for Clinical Standards and Quality
Rhonda Medows, M.D., FAAFP, Executive Vice President and Chief Medical Officer, UnitedHealthcare
Robert Metcalf, Ph.D., Vice President, Global Regulatory Affairs – U.S., Eli Lilly and Co.
Theresa M. Mullin, Ph.D., Associate Director, Office of Planning and Informatics, Center for Drug Evaluation and Research
J. Russell Teagarden, Senior Vice President, Medical and Scientific Affairs, National Organization for Rare Disorders

ABOUT DIA: DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and life cycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C.; and Latin America. Visit our website at http://www.diahome.org and follow DIA at: LinkedIn, Twitter, YouTube, Facebook, Flickr and Pinterest.


Contact